Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hemoglobin Stabilization and Transfusion Reduction with Eculizumab in Paroxysmal Nocturnal Hemoglobinuria
2004-000646-20Phase 3Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Jul 2004
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in paroxysmal nocturnal hemoglobinuria (PNH) comparing Eculizumab with Placebo (2 arms). Primary endpoints: Hemoglobin stabilization and Number of PRBC units transfused. Started Jul 2004; status: completed.
02
Drugs
eculizumab
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on 2004-000646-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000646-20.